Now mind you, what I said explains the lack of widespread promotion and DTC advertising. I do find the stock price somewhat suspicious. Another thing I saw first hand in my 14 years in pharma was ”inexplicable“ actions (or inaction) by execs that suppressed share price. Usually, it preceded a buyout. The suppressive actions, I realized in retrospect, had served to keep the share price in a range that pleased a pre-determined buyer. I have no insider knowledge here, but I would be very surprised if a major pharma company does not scoop this up. With Big Pharma marketing muscle— and Big Pharma R&D budgets to initiate a trial for males— this drug has limitless potential, in my opinion. Limitless. That’s why I’m long.